Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

BACKGROUND: The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the effect of dulaglutide on CV risk factors could statistically account for its eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Konig, Manige, Riddle, Matthew C., Colhoun, Helen M., Branch, Kelley R., Atisso, Charles M., Lakshmanan, Mark C., Mody, Reema, Raha, Sohini, Gerstein, Hertzel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466679/
https://www.ncbi.nlm.nih.gov/pubmed/34563178
http://dx.doi.org/10.1186/s12933-021-01386-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466679/
https://www.ncbi.nlm.nih.gov/pubmed/34563178
http://dx.doi.org/10.1186/s12933-021-01386-4

Ejemplares similares